Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry

Cortical cholinergic deficiency is prominent in Alzheimer's disease (AD), and published findings of diminished pupil flash response in AD suggest that this deficiency may extend to the visual cortical areas and anterior eye. Pupillometry is a low-cost, noninvasive technique that may be useful for monitoring cholinergic deficits which generally lead to memory and cognitive disorders. The aim of the study was to evaluate pupillometry for early detection of AD by comparing the pupil flash response (PFR) in AD (N = 14) and cognitively normal healthy control (HC, N = 115) participants, with the HC group stratified according to high (N = 38) and low (N = 77) neocortical amyloid burden (NAB). Constriction phase PFR parameters were significantly reduced in AD compared to HC (maximum acceleration p < 0.05, maximum velocity p < 0.0005, average velocity p < 0.005, and constriction amplitude p < 0.00005). The high-NAB HC subgroup had reduced PFR response cross-sectionally, and also a greater decline longitudinally, compared to the low-NAB subgroup, suggesting changes to pupil response in preclinical AD. The results suggest that PFR changes may occur in the preclinical phase of AD. Hence, pupillometry has a potential as an adjunct for noninvasive, cost-effective screening for preclinical AD.

[1]  Helmut Wilhelm,et al.  Clinical applications of pupillography. , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[2]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[3]  Bruno Dubois,et al.  Cholinergic deficiency and frontal dysfunction in Parkinson's disease , 1990, Annals of neurology.

[4]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[5]  Satoshi Takahashi,et al.  Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia , 1994, Neuroscience Letters.

[6]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[7]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[8]  J. Michael Textbook of Medical Physiology , 2005 .

[9]  A Tales,et al.  The pupillary light reflex in aging and Alzheimer's disease. , 2001, Aging.

[10]  Karl Herholz,et al.  In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease , 2004, NeuroImage.

[11]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[12]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[13]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[14]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[15]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[16]  Chrysa D. Lithari,et al.  Cholinergic deficiency in Alzheimer's and Parkinson's disease: evaluation with pupillometry. , 2009, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[17]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[18]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[19]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[20]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[21]  Bruno Vellas,et al.  Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force , 2013, Alzheimer's & Dementia.

[22]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[23]  W. Markesbery,et al.  Neuropathologic alterations in mild cognitive impairment: a review. , 2010, Journal of Alzheimer's disease : JAD.

[24]  E. Szabadi,et al.  Altered pupillary size and darkness and light reflexes in Alzheimer's disease. , 1997, Journal of Neurology Neurosurgery & Psychiatry.

[25]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[26]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[27]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[28]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[29]  M. Molaschi,et al.  Is videopupillography useful in the diagnosis of Alzheimer's disease? , 1998, Neurology.

[30]  Yogesan Kanagasingam,et al.  Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. , 2013, Current Alzheimer research.

[31]  Eric M Reiman,et al.  The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[32]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[33]  Eric Granholm,et al.  Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. , 2003, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[34]  M. Tsolaki,et al.  Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[35]  S Ourselin,et al.  β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.

[36]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[37]  W. Marsden I and J , 2012 .

[38]  Anna-Bettina Haidich,et al.  Pupil reaction to light in Alzheimer’s disease: evaluation of pupil size changes and mobility , 2007, Aging clinical and experimental research.

[39]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[40]  C. Rowe,et al.  Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings , 2008 .

[41]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[42]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[43]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.